Best Immunotherapy for Cancer in Dubai

Best Immunotherapy for Cancer in Dubai - Dr. Ajeet Tiwari

Immunotherapy has become one of the most talked-about cancer treatments in Dubai over the last few years, and for good reason. It can produce durable results in cancers that used to be difficult to control, and it often comes with a different, sometimes gentler, side-effect profile than chemotherapy. But it is also one of the most misunderstood treatments, because it does not work for every cancer, and it does not work for every patient with the same cancer either. Eligibility is specific, testable, and needs to be confirmed before anyone commits to a treatment plan.

Dr. Ajeet Tiwari is an MCh surgical oncologist who reviews immunotherapy eligibility for patients in Dubai, walks through what the biomarker results actually mean in plain language, and puts together a treatment plan when immunotherapy is a genuine option, either on its own or alongside chemotherapy, surgery or targeted therapy.

Book a Consultation

This page explains how that eligibility decision is made, what it costs, and what the treatment itself looks like week to week.

What Immunotherapy Actually Does

Cancer cells are often able to hide from the immune system by producing proteins that switch off the immune cells sent to attack them. Immunotherapy drugs, most commonly a class called checkpoint inhibitors, block that switch-off signal, which allows the body's own immune system to recognise the cancer cells again and attack them directly. This is fundamentally different from chemotherapy, which works by killing rapidly dividing cells regardless of whether the immune system is involved at all.

How Checkpoint Inhibitors Work

The two most common checkpoint targets are PD-1, found on immune cells, and PD-L1, found on cancer cells. When a PD-1 inhibitor or PD-L1 inhibitor is given, it blocks this interaction, effectively removing the brake that was stopping the immune system from doing its job. The strength of this effect varies a great deal by cancer type and by how much PD-L1 the tumor is actually expressing, which is why testing comes before treatment, not after.

When Immunotherapy Is Combined With Other Treatments

For a number of cancers, immunotherapy is not used as a stand-alone treatment but combined with chemotherapy, targeted therapy, or given after surgery to reduce the chance of recurrence. The combination that makes sense depends entirely on the cancer type, stage, and biomarker profile, and is one of the main things reviewed during your initial consultation.

Best Immunotherapy for Cancer in Dubai: How Eligibility Is Actually Decided

There is no single test that says yes or no to immunotherapy across the board. Eligibility depends on a combination of factors specific to your tumor, and these are usually established from the same biopsy or surgical tissue sample already sitting in a pathology lab, which means eligibility can often be checked without any new procedure.

Factor	What It Tells the Treating Team
PD-L1 expression	How much of the checkpoint protein the tumor is producing, which helps predict response to PD-1/PD-L1 inhibitors.
Microsatellite instability (MSI) status	Whether the tumor has a DNA repair defect that tends to respond well to immunotherapy across several cancer types.
Tumor mutation burden	How many genetic mutations the tumor carries; higher counts are sometimes linked to a stronger immunotherapy response.
Cancer type and stage	Some cancers respond well to immunotherapy as standard practice; others have limited or no established benefit.
Prior treatment history	What has already been tried and how the tumor responded, which shapes whether immunotherapy is used alone or combined.

None of these factors are assessed in isolation. They are read together against your specific diagnosis, which is exactly why a proper second opinion, not a general assumption based on cancer type alone, is the right first step.

Immunotherapy vs Chemotherapy: What's Actually Different

Patients in Dubai often ask whether immunotherapy simply replaces chemotherapy. It does not, and the two are not interchangeable, even though they are sometimes used together. The table below sets out the practical differences that tend to matter most when a patient is deciding between, or combining, the two.

Aspect	Chemotherapy	Immunotherapy
How it works	Directly kills rapidly dividing cells, including cancer cells	Helps the immune system recognise and attack cancer cells
Typical side effects	Nausea, fatigue, hair loss, low blood counts	Fatigue, skin reactions, occasional inflammation in organs
Who it suits	Most solid tumors, often as a standard first step	Only cancers and patients matching specific biomarker criteria
Testing required first	General blood work and imaging	Biomarker testing such as PD-L1 or MSI status
Typical schedule	Cycles every 2–3 weeks over several months	Infusions every 2–4 weeks, often for a defined treatment period

Immunotherapy Cost for Cancer Patients in Dubai

Immunotherapy drugs are among the more expensive cancer treatments anywhere in the world, and cost varies significantly depending on the specific drug, the number of infusions needed, and whether it is given alone or combined with chemotherapy. Rather than quoting a general figure that would not actually apply to your case, a written cost estimate is provided once your cancer type, stage, and biomarker results are known, so you have a specific number to work with rather than a wide range.

What an Immunotherapy Treatment Cycle Involves

Treatment is given as an intravenous infusion, typically every two to four weeks depending on the specific drug and protocol used. Each infusion visit usually takes a few hours in a day-care setting and does not require an overnight hospital stay for most patients. Response is checked periodically through repeat imaging, generally every two to three months, to confirm the treatment is working before continuing the same plan or adjusting it.

How Long Treatment Typically Continues

Some immunotherapy protocols run for a fixed period, often around one to two years, while others continue as long as the treatment is working and side effects remain manageable. This is decided based on how your specific cancer responds and is reviewed at each scan, not fixed in advance.

Managing Immune-Related Side Effects

Because immunotherapy works by activating the immune system rather than suppressing rapidly dividing cells, its side effects look different from chemotherapy and can, less commonly, affect organs such as the lungs, liver, thyroid or gut through an overactive immune response.

Common Side Effects

Most patients experience mild fatigue, occasional skin rash or itching, and sometimes joint discomfort, all of which are generally manageable with routine supportive care alongside treatment.

When to Seek Urgent Care

Less common but more serious reactions, such as persistent diarrhoea, shortness of breath, or unusual fatigue accompanied by other symptoms, need prompt attention rather than waiting for the next scheduled review. You are given clear written guidance on exactly what to watch for and who to contact if something feels off between visits.

Immunotherapy for Cancer Patients in Riyadh, Jeddah and Kuwait

This eligibility review and treatment planning process is not limited to patients based in Dubai. Cancer patients researching immunotherapy in Riyadh and Jeddah, Saudi Arabia, and in Kuwait use the same process described on this page: sending existing pathology and biomarker reports for review, a video consultation to discuss eligibility, and a written treatment and cost plan before any decision is made. Distance from Dubai does not change how the eligibility assessment works, only the specific travel arrangements involved.

How to Get Your Case Reviewed for Immunotherapy Eligibility

If you already have a biopsy, surgical pathology, or biomarker report, send it through the online second opinion page. If biomarker testing has not yet been done, this is flagged during the initial review so it can be arranged before any decision on immunotherapy is finalised. From there, a video consultation covers whether immunotherapy applies to your case, what it would cost, and what an alternative plan would look like if it does not.

Frequently Asked Questions

Find answers to common questions about immunotherapy, eligibility, biomarker testing, treatment costs, and international patient care.

Eligibility depends on your cancer type, stage, and specific biomarker results such as PD-L1 expression or microsatellite instability status. This is confirmed after reviewing your pathology report, not assumed from your diagnosis alone.

The initial review and consultation happen by video call, so you know your eligibility and treatment plan before making any decisions. If immunotherapy or surgery is recommended and you choose to proceed, treatment takes place at Dr. Tiwari's hospital, with full details on travel and logistics explained clearly in advance.

Generally yes, immunotherapy drugs tend to cost more per cycle than standard chemotherapy, though the total cost depends heavily on the specific drug, number of cycles, and whether it is combined with other treatments. A written estimate is given once your plan is confirmed.

PD-L1 testing checks how much of a specific protein your tumor is producing, which helps predict how likely it is to respond to certain immunotherapy drugs. For many cancer types, this or a related biomarker test is required before immunotherapy is recommended, though the exact requirement depends on the cancer involved.

Yes, for a number of cancers this combination is standard practice, while for others immunotherapy is used alone or not indicated at all. This depends entirely on your specific cancer type and stage.

Yes. Patients from Riyadh, Jeddah, and Kuwait use the same review and consultation process described on this page.

Best Immunotherapy for Cancer in Dubai

Get Consultation